Laquinimod dampens IL-1β signaling and Th17-polarizing capacity of monocytes in patients with MS.
Sinah EngelValérie JolivelStefan H-P KrausMorad ZayoudKarolina RosenfeldHayrettin TumaniRoberto FurlanFlorian C KurschusEsther Von StebutFelix LuessiPublished in: Neurology(R) neuroimmunology & neuroinflammation (2020)
Our findings suggest that inhibited NF-κB signaling and downregulation of IL-1β expression in monocytes contributes to the immunomodulatory effects of laquinimod and that the impairment of Th17 polarization might mediate its disease-modifying activity in MS.